{"id":"adefovir-entecavir","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Elevated creatinine/renal dysfunction (adefovir)"},{"rate":null,"effect":"Lactic acidosis (rare)"}]},"_chembl":{"chemblId":"CHEMBL713","moleculeType":"Small molecule","molecularWeight":"277.28"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both drugs are nucleoside analogues that are phosphorylated intracellularly and incorporated into the growing HBV DNA chain, causing chain termination and preventing viral replication. Entecavir is a guanosine analogue with higher potency and lower resistance rates compared to adefovir. Adefovir is an adenosine monophosphate analogue that also inhibits HBV polymerase with activity against lamivudine-resistant strains.","oneSentence":"Adefovir and entecavir are nucleoside/nucleotide reverse transcriptase inhibitors that block hepatitis B virus (HBV) replication by inhibiting viral polymerase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:58.207Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection"},{"name":"Lamivudine-resistant hepatitis B (adefovir)"}]},"trialDetails":[{"nctId":"NCT04102176","phase":"NA","title":"Halting Nucleoside Analogues in Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seng Gee Lim","startDate":"2019-01-29","conditions":"Chronic Hepatitis B","enrollment":120},{"nctId":"NCT03736265","phase":"NA","title":"Carvedilol for Prevention of Esophageal Varices Progression","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2017-10-09","conditions":"Cirrhosis, Liver, Portal Hypertension","enrollment":240},{"nctId":"NCT00704106","phase":"","title":"Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders","status":"COMPLETED","sponsor":"Pacific Health Foundation","startDate":"2008-05","conditions":"Hepatitis B","enrollment":60},{"nctId":"NCT05406089","phase":"","title":"Effects of Antiviral Therapy on Patients With HBV-related HCC","status":"COMPLETED","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2016-01-01","conditions":"Hepatocellular Carcinoma, Hepatitis B Virus, Survival","enrollment":494},{"nctId":"NCT05021406","phase":"NA","title":"Extension Study of Carvedilol RCT Study","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2021-01-08","conditions":"Liver Cirrhosis, Portal Hypertension","enrollment":240},{"nctId":"NCT03491553","phase":"PHASE2","title":"Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-04-06","conditions":"Chronic Hepatitis B","enrollment":48},{"nctId":"NCT04724785","phase":"","title":"Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2020-12-01","conditions":"Sustained Virologic Response, Hepatitis B, Chronic","enrollment":10000},{"nctId":"NCT03366571","phase":"","title":"Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2016-01","conditions":"Chronic Hepatitis B","enrollment":600},{"nctId":"NCT03241641","phase":"PHASE4","title":"Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.","status":"COMPLETED","sponsor":"Young-Suk Lim","startDate":"2017-10-26","conditions":"Chronic Hepatitis b","enrollment":174},{"nctId":"NCT01373684","phase":"PHASE4","title":"PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2012-05-25","conditions":"Chronic Hepatitis B","enrollment":90},{"nctId":"NCT01943799","phase":"PHASE2","title":"Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-09-13","conditions":"Chronic HBV Infection","enrollment":178},{"nctId":"NCT01928511","phase":"PHASE4","title":"Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy","status":"COMPLETED","sponsor":"Seng Gee Lim","startDate":"2014-01","conditions":"Chronic Hepatitis B","enrollment":254},{"nctId":"NCT01639066","phase":"PHASE4","title":"Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2012-09-25","conditions":"Chronic Viral Hepatitis B Without Delta-agent","enrollment":102},{"nctId":"NCT03253250","phase":"PHASE4","title":"The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2017-09-01","conditions":"Chronic Hepatitis b, Hepatic Carcinoma","enrollment":432},{"nctId":"NCT03084250","phase":"PHASE4","title":"The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC","status":"UNKNOWN","sponsor":"Shanghai Nanhui Nanhua Hospital","startDate":"2017-03-10","conditions":"Hepatitis B","enrollment":150},{"nctId":"NCT00922207","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-05-07","conditions":"Hepatitis B, Chronic","enrollment":280},{"nctId":"NCT01706575","phase":"PHASE2","title":"A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-01","conditions":"Hepatitis B, Chronic","enrollment":76},{"nctId":"NCT02327416","phase":"PHASE3","title":"A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2014-10","conditions":"Hepatitis B, Chronic","enrollment":300},{"nctId":"NCT02644538","phase":"PHASE4","title":"Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2015-12","conditions":"Hepatitis B","enrollment":196},{"nctId":"NCT02482272","phase":"PHASE4","title":"Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2015-05","conditions":"Hepatitis B, Chronic","enrollment":90},{"nctId":"NCT02560649","phase":"PHASE4","title":"An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2015-05","conditions":"Chronic Hepatitis B","enrollment":324},{"nctId":"NCT00986778","phase":"PHASE4","title":"Entecavir Plus Adefovir in Lamivudine-Resistant Patients","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Hepatitis B, Chronic","enrollment":""},{"nctId":"NCT01720238","phase":"","title":"Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2012-03","conditions":"Liver Cirrhosis, Hepatitis B","enrollment":621},{"nctId":"NCT02005146","phase":"","title":"Retrospective Observational Study to Define HBsAg Loss With or Without Seroconversion to antiHBs in Patients With Chronic Hepatitis by B Virus Treated With Nucleoside/Nucleotide Analogs","status":"COMPLETED","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2013-12","conditions":"Chronic Hepatitis B Treated With Nucleoside/Nucleotide Analogues","enrollment":86},{"nctId":"NCT02075294","phase":"","title":"Efficacy and Safety Study of Adefovir and Entecavir for Elderly With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Ying-Jie Ji","startDate":"2010-01","conditions":"Hepatitis B, Chronic","enrollment":242},{"nctId":"NCT01829685","phase":"PHASE4","title":"Efficacy Optimizing Extension Study of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2013-03","conditions":"Chronic Hepatitis B, Inadequate Response, Nucleos(t)Ide Analogues Treatment","enrollment":360},{"nctId":"NCT01834508","phase":"PHASE4","title":"3E Extension Study","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2013-03","conditions":"Chronic Hepatitis B","enrollment":600},{"nctId":"NCT01546116","phase":"PHASE4","title":"Adefovir and Lamivudine for Entecavir Resistance (ALTER Study)","status":"COMPLETED","sponsor":"Korea University","startDate":"2010-02","conditions":"Chronic Hepatitis B","enrollment":20},{"nctId":"NCT01023217","phase":"PHASE4","title":"Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2009-11","conditions":"Hepatitis B, Chronic","enrollment":90},{"nctId":"NCT01597934","phase":"PHASE4","title":"Antiviral Efficacy of Switching to ETV Plus TDF","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2012-08","conditions":"Chronic Hepatitis B","enrollment":104},{"nctId":"NCT00410202","phase":"PHASE3","title":"Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-03","conditions":"Hepatitis B, Chronic","enrollment":629},{"nctId":"NCT01341743","phase":"PHASE4","title":"Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2010-12","conditions":"Hepatitis B","enrollment":360},{"nctId":"NCT01844063","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Diverse Mesenchymal Stem Cells Transplantation for Liver Failure","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2013-07","conditions":"Liver Failure","enrollment":210},{"nctId":"NCT00065507","phase":"PHASE3","title":"Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2003-08","conditions":"Hepatitis B","enrollment":195},{"nctId":"NCT00718887","phase":"PHASE4","title":"Suboptimal Responders to Adefovir Switching to Entecavir","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-07","conditions":"Hepatitis B, Chronic","enrollment":228},{"nctId":"NCT01718587","phase":"PHASE1, PHASE2","title":"Difference in Efficacy Between Stem Cell Transplantation and Classical Therapy in Liver Cirrhosis Patients","status":"UNKNOWN","sponsor":"General Hospital of Chinese Armed Police Forces","startDate":"2012-11","conditions":"Liver Cirrhosis","enrollment":60},{"nctId":"NCT00531167","phase":"PHASE4","title":"Adding Adefovir Dipivoxil Versus Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B","status":"COMPLETED","sponsor":"Korea University","startDate":"2007-04","conditions":"Chronic Hepatitis B","enrollment":219},{"nctId":"NCT01595633","phase":"PHASE4","title":"Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2012-03","conditions":"Chronic Hepatitis B","enrollment":124},{"nctId":"NCT00605384","phase":"PHASE3","title":"A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2008-08","conditions":"Chronic Hepatitis B","enrollment":4},{"nctId":"NCT00096785","phase":"PHASE3","title":"Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-12","conditions":"Hepatitis B, Chronic Disease","enrollment":69},{"nctId":"NCT01155427","phase":"","title":"Systematic Review of Antiretroviral Treatments for Chronic Hepatitis B (CHB)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-05","conditions":"Hepatitis B, Chronic","enrollment":100},{"nctId":"NCT01139203","phase":"NA","title":"Prophylaxis of Hepatitis B Virus Recurrence After Liver Transplantation","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2009-08","conditions":"Liver Transplantation, Hepatitis B","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Baraclude","BMS-200475"],"phase":"marketed","status":"active","brandName":"Adefovir/Entecavir","genericName":"Adefovir/Entecavir","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adefovir and entecavir are nucleoside/nucleotide reverse transcriptase inhibitors that block hepatitis B virus (HBV) replication by inhibiting viral polymerase. Used for Chronic hepatitis B infection, Lamivudine-resistant hepatitis B (adefovir).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}